NEW YORK (GenomeWeb) – Abbott today announced the US Food and Drug Administration approved its RealTime CMV molecular test, the only commercially available cytomegalovirus test that can amplify two select regions of the CMV genome, according to the company.

The dual target capability of the assay reduces the risk of underquantitation or failure to detect the virus, a known concern with CMV infections because of possible mutations of the virus, Abbott said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.